2017 nine-month & third-quarter sales
|
|
- Milton Nelson
- 6 years ago
- Views:
Transcription
1 2017 nine-month & third-quarter sales Webcast presentation for investors, analysts & media Basel, 26 October 2017 Disclaimer This presentation contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. The Group is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise. The availability and indications/claims of the products illustrated and mentioned in this presentation may vary according to country. 2 1
2 9-months highlights Marco Gadola, CEO Growth throughout and beyond our space REVENUE GROWTH TOP PERFORMER BUSINESS DRIVERS +15% organic 1 North America Total solutions : +16% organic; +21% in CHF 9M: +15% organic; +19% in CHF generates >30% of Group s 9M growth; APAC remains fastest-growing region (+24%) Implants contribute two thirds of 9M growth: BLT and Neodent CM drive premium and non-premium businesses respectively. EXPANSION PRODUCTS OUTLOOK New subsidiaries Regulatory approvals Raised Iran opened; preparations for subsidiaries in Turkey & S. Africa underway. Acquisitions of ClearCorrect & Dental Wings completed. for key Straumann products (including BLT) in China, Russia and India. Neodent launches new GM implant system. for full-year organic revenue growth: 13-15% Organic growth i.e. excluding the effects of currency fluctuations and acquired/divested business activities 2 Outlook expectations barring unforeseen events/circumstances 2
3 Momentum sustained in with accelerations in APAC and LATAM Growth year-on-year (in %) North America 28% of Group EMEA 44% of Group APAC 17% of Group M LATAM 11% of Group M 9M Straumann Group M 9M Consistently outperforming the market Organic revenue growth since % 14.8% >3x market growth (incl. Straumann Group) Average 7.2% 6.4% 9.1% Double-digit growth over the first 9 months supported across all segments 1.2% -1.0% M Biomaterials ++ Implants ++ Restorative 6 3
4 Business and regional review Peter Hackel, CFO Further expansion across all regions Revenue development (CHFm, rounded) % CHF % organic 27.0 Change in organic growth Regional share of organic growth 12% LATAM 26% 31% APAC North America 10.0% 17.2% 24.2% 15.7% 31% EMEA Revenues 9M 2016 FX effect M&A effect Revenues 9M FX 2017 EMEA North America APAC LATAM Revenues 9M
5 EMEA and North America maintain pace EMEA 44% of Group 11.1% Revenue change (organic) 56% 7.7% 8.0% 10.1% 9.9% 9.9% EMEA performed consistently throughout the first 9-months Germany was the main contributor, with Iberia, France, Belgium and the UK delivering the strongest increases Dynamic growth in Russia North America 28% of Group 16.9% 17.3% Q4 Q % 16.0% 17.2% 17.0% Double-digit growth in both the premium and non-premium implant businesses Higher levels of sales generated from newly acquired customers Many new customers attracted by Straumann s novel 2.9mm BLT implant Q4 Q Asia Pacific and Latin America on fast track APAC 17% of Group Revenue change (organic) 56% 20.2% 17.0% 25.7% 20.5% 19.4% 27.9% China continues to be main powerhouse; Anthogyr adds to growth Double-digit increases in Australia, China, South Korea, and Japan Japan posts strongest quarter this year Latin America 11% of Group 17.2% 12.7% Q4 15.0% Q % 12.8% 18.9% Straumann and Neodent gain new customers in weak Brazilian market Successful launch of Neodent GM Dynamic growth in Mexico; earthquake disruption not evident in New subsidiaries in Argentina, Colombia, and Chile complete build-up phase Q4 Q
6 Capacity expansion to meet growing demand Facility Output increase 1 Villeret (CH) New production building (brownfield) +70% Andover (US) +60% Curitiba (BR) +35% +50% space New production area in Curitiba Impression of new production building in Villeret 11 1 Expected capacity increase from H Q New building/ modification Additional machine capacity or working hours Strategic progress Marco Gadola, CEO 6
7 Strategic priorities of the Straumann Group Drive our high performance STMN Group culture and organization Target unexploited growth markets & segments Expand scope to become a Total Solution Provider for esthetic dentistry 13 Geographical expansion reflected in an increasingly diverse team Employees by region (in % of total 1 ) Headcount development (pro forma 1 ) NAM 19% APAC 10% CH (incl. HQ) 20% 3'471 3' '290 2'217 2' LATAM 25% Rest of EMEA 26% M 2017 Number of employees Medentika & Equinox Dental Wings & ClearCorrect 14 1 Incl. Dental Wings and ClearCorrect, which were consolidated as of
8 New subsidiaries in Iran, Turkey & South Africa direct access to large growth markets Iran Distribution taken over Broader presence; multi-brand strategy Straumann products available in Iran since ( ) Turkey Preparations to establish subsidiary in coming months Intention to incorporate current distributor & team South Africa Straumann ranks among top 3 premium companies Preparations to open subsidiary, incorporating former distributor & team Cape Town subsidiary to act as regional hub Implants per people (implant market total) 13 (60 000) 75 ( ) 15 Chinese fire-cracker Key regulatory approvals obtained; launches underway for: Straumann BLT implants Roxolid SLActive for practically all Straumann implants Straumann Pro Arch edentulous solutions Straumann Smart enablement & education program Anthogyr Axiom PX implants Launch activities include 3-day Innovation Summit in Shanghai with parallel congresses in Beijing, Guangzhou & Chengdu; large number of participants expected (1600 onsite and online yesterday). New CADCAM milling center in Shenzhen operational in 2018 Straumann BLT Anthogyr Axiom PX 16 8
9 Other significant regulatory approvals and launches Russia Straumann Bone Level Tapered implant approved India All Straumann Soft Tissue Level & Bone Level implants approved Major launch event in Mumbai early December Group now offers a comprehensive range of premium & attractively-priced implant options under the Straumann & Equinox brands. 17 Neodent launches innovative Grand Morse implant system in Brazil Complete new implant system for all clinical needs, developed from the inside out, starting with the prosthetic interface Fully tapered design with cutting threads Comprehensive prosthetic range, including angulated rounded abutments for full-arch restorations, ti-bases and ProPeek temporary abutments 1-year clinical evidence: 100% survival of 277 implants in 57 patients new customers attracted in first month Roll-out in other regions beginning mid 2018 Grand Morse is expected to become the preferred choice of Neodent customers and to supersede the Cone Morse in the next two years Data on file 9
10 EAO in Madrid New products despite big launch program at IDS Straumann P-Series 3D printers enter market Dental Wings powder-free intraoral scanner handpiece Straumann Surgical Motor Pro Clinical endorsements for Straumann solutions at scientific symposium, focusing on patient-centric protocols, edentulous solutions with Pro Arch and Novaloc, and immediacy with BLT 19 Exciting new data on SLActive implant surface Discovery of distinct nanostructures on the SLActive surface 1,2 proves its topography differs from that of SLA. Presence of nanostructures increases surface area by 50% 3 Roxolid SLA Roxolid SLActive Roxolid SLA Roxolid SLA with nanostructures Roxolid SLActive with nanostructures enhances (together with surface wettability) fibrin network formation cell adhesion bone-cell mineralization osseointegration 2,4,5 Fibrin network Adherent cells 20 1 Kopf BS et al The role of nanostructures and hydrophilicity in osseointegration: In-vitro protein-adsorption and blood-interaction studies. J Biomed Mater Res Part A2015:103A: Wennerberg A et al. Nanostructures and hydrophilicity influence osseointegration A biomechanical study in the rabbit tibia. Clin. Oral Impl. Res. 25, 2014, Straumann: data on file 4 Müller E et al. The interplay of surface chemistry and (nano-)topography defines the osseointegrative potential of Roxolid dental implant surfaces. ecm Meeting Abstracts 2017, Collection 3; SSB+RM (page 31). 5 EMPA (2017) Report additional experiments: Impact of RXD SLA, RXD SLAnano, RXD SLActive, and RXD pmod SLA surfaces on protein adsorption, blood coagulation, and osteogenic differentiation of HBCs. Final report: Impact of RXD SLA, RXD SLAnano, RXD SLActive, and RXD pmod SLA surfaces on protein adsorption, blood coagulation, and osteogenic differentiation of HBCs. EMPA, Swiss Federal Laboratories for Materials Science and Technology (data on file). 10
11 Strategic priorities of the Straumann Group Drive our high performance STMN Group culture and organization Target unexploited growth markets & segments Expand scope to become a Total Solution Provider for esthetic dentistry 21 Dental Wings, ClearCorrect & Rapid Shape transactions closed Ownership 100% 100% 38% 35% 22 Footnote 11
12 The orthodontic workflow complements our digital solutions for esthetic dentistry Case design Treatment design Doctor approval Prosthetic workflow Orthodontic workflow Doctor approval Data capturing Production 23 Tooth-borne implant -borne restorations Aligner production Model production Outlook
13 Outlook for 2017 Barring unforeseen circumstances Market growth We expect the global implant market to grow at approx. 3-4% 1 in 2017 Our revenue growth Confident that we can continue to outperform by achieving organic 2 revenue growth of 13-15% Profitability Further improvements in the underyling 2 operating profit margin despite further investments in strategic growth initiatives 25 1 Market growth assessment incl. Straumann Group 2 excl. currency and acquisition effects (ClearCorrect, Dental Wings, Medentika, and Equinox). Questions & answers & 13
14 Calendar of upcoming events 2017 Event Location 26 October /9M revenue publication Webcast 28 October Investor meetings Paris (F) 31 October Investor meetings Geneva (CH) 16 November Vontobel Healthcare Tour Basel (CH) 17 November Credit Suisse Mid-cap conference Zurich (CH) 23 November HSBC Equities conference Frankfurt (D) 07 December Berenberg Equities conference Pennyhill (UK) 2018 Event Location 15 February Full-year 2017 results conference Straumann Group Headquarters, Basel 04 April AGM 2018 Messe Basel 27 Growth strategy pays off in CHF million M year average Revenue Organic revenue growth in % Acquisiton / Divesture effect in % Change in l.c.% FX effect in % Growth in CHF % H CAGR Gross profit b. exceptionals Underlying margin 77.9% 78.8% 78.7% 78.6% 78.3% 77.2% EBIT b. exceptionals Underlying margin 14.9% 18.2% 20.9% 23.3% 24.8% 25.7% Underlying net profit Underlying margin 10.6% 15.9% 18.4% 18.1% 20.4% 21.6% Earnings per share (adjusted) H CAGR Operating cash flow Capital expenditure (19.4) (12.6) (18.8) (35.2) (46.7) (32.8) as % of revenue -2.8% -1.9% -2.6% -4.4% -5.1% -4.1% Free cash flow Number of employees (year-end) 1 2'517 2'217 2'387 3'471 3'797 4' In March 2015 Straumann acquired the remaining 51% stake of Neodent (Brazil) which added 930 employees to the Group. In 2017, the incorporation of Equinox in India and Medentika in Germany added 160 employees. Note: 5-year average = M
15 Straumann s currency exposure Revenue breakdown FY CHF Other 8% 15% BRL 10% JPY 7% EUR 31% FX sensitivity Average exchange rates (rounded) (+/- 10%) on full-year... 9M M 2017 Latest trend Revenue EBIT 1 EURCHF /- 29m +/- 18m 1 USDCHF /- 23m +/- 11m 100 BRLCHF /- 9m +/- 3m 100 JPYCHF /- 6m +/- 4m USD/CAD/AUD 30% Cost breakdown FY BRL 9% JPY 4% Other 9% CHF 36% Development of Straumann s main exchange rates since USD/CAD/AUD 23% EUR 19% USDCHF EURCHF JPYCHF BRLCHF 29 1 These distribution charts represent the total net revenues and the total COGS, as well as OPEX in the various currencies. All numbers are rounded and based on FY 2016 figures. Thank you investor.relations@straumann.com 15
Straumann Group raises full-year revenue outlook as organic 1 growth reaches 15% in first nine months
Media Release Straumann Group raises full-year revenue outlook as organic 1 growth reaches 15% in first nine months 9-month revenue climbs 19% in Swiss francs to CHF 801 million Q3 revenue rises 21% in
More informationCreating opportunities. Fabian Hildbrand, Investor Relations & Market Research VP Bad Ragaz, 12 January 2017
Creating opportunities Fabian Hildbrand, Investor Relations & Market Research VP Bad Ragaz, 12 January 2017 Disclaimer This presentation contains certain forward-looking statements that reflect the current
More informationmonths sales presentation Webcast for investors, analysts & media
2016 9-months sales presentation Webcast for investors, analysts & media Basel, 27 October 2016 1 Disclaimer This presentation contains certain forward-looking statements that reflect the current views
More informationStraumann Group sustains strong performance, as organic revenue rises 18% both in Q3 and over the first nine months of 2018
2018 Nine-months sales report Media Release Straumann Group sustains strong performance, as organic revenue rises 18% both in Q3 and over the first nine months of 2018 Revenue growth in Swiss Francs reaches
More informationStraumann on track with organic 1 growth of 9% in first 9 months
Media release Straumann on track with organic 1 growth of 9% in first 9 months Group revenue climbs 12% in Swiss francs (9% organic, 18% in local currencies) to CHF 585m, including CHF 46m from Neodent
More informationCreating opportunities for customers and shareholders. Berenberg Equities Conference, Pennyhill, 05 December 2018
Creating opportunities for customers and shareholders Berenberg Equities Conference, Pennyhill, 05 December 2018 Disclaimer This presentation contains certain forward-looking statements that reflect the
More informationmonths sales presentation Webcast for investors, analysts & media
2015 9-months sales presentation Webcast for investors, analysts & media Basel, 29 October 2015 Disclaimer This presentation contains certain forward-looking statements that reflect the current views of
More informationStraumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America
Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset
More informationStraumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010
Media release Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010 Growth driven by implant volumes, lifted by Bone Level implant range and Roxolid Third quarter (+3%
More informationTo be the partner of choice Straumann
To be the partner of choice Straumann Gilbert Achermann, CEO Helvea Swiss Equities Conference 11 January 2008, Bad Ragaz Table of contents 1. A snapshot of Straumann 2. Financials 3. Markets and opportunities
More informationBeing the partner of choice. Beat Spalinger, CEO & President presenting at the 2011 Berenberg European conference
Being the partner of choice Beat Spalinger, CEO & President presenting at the 2011 Berenberg European conference Disclaimer This presentation contains certain forward-looking statements, which can be identified
More informationHalf-year 2008 Road Show
Half-year 2008 Road Show Disclaimer This presentation contains certain forward-looking statements, which can be identified by use of terminology such as expect, expectation, intend, continue, achieve,
More informationBeing the partner of choice
Being the partner of choice Beat Spalinger, President & CEO at the Sanford Bernstein Conference 2012, London Disclaimer This presentation contains certain forward-looking statements, which can be identified
More informationTaking an important step towards our goal of becoming a total solution provider. International Dental Show (IDS) Cologne, 12 March 2015
Taking an important step towards our goal of becoming a total solution provider International Dental Show (IDS) Cologne, 12 March 2015 1 Today s speakers Marco Gadola, CEO 5 years with the company Dr Gerhard
More informationA reliable solution provider. Gilbert Achermann, CEO Sanford Bernstein Strategic Conference 2009
A reliable solution provider Gilbert Achermann, CEO Sanford Bernstein Strategic Conference 2009 Agenda Straumann in brief Future market dynamics Recent market trends Straumann further sustainable growth
More informationUnited for global excellence in dentistry.
United for global excellence in dentistry. TRADITION Rooted in a tradition of legendary Swiss engineering GLOBAL REACH Global reach through subsidiaries and distributors in more than 100 countries INNOVATION
More informationFueling innovation in the premium dental market
Fueling innovation in the premium dental market Francisco Faoro Head Product Development BUSurgical 8 October 2012 Straumann a global leader in replacement, restorative and regenerative dentistry A pioneer
More informationWE CREATE OPPORTUNITIES
2016 ANNUAL REPORT WE CREATE OPPORTUNITIES For learners: Education courses; ITI Academy; Straumann Smart education concept; corporate forums at key events; ITI Study Clubs For specialists: Peer-to-Peer
More informationINNOVATION 35 MARKETS
MANAGEMENT COMMENTARY 18 23 27 32 INNOVATION 35 MARKETS 43 49 56 58 60 BUSINESS MODEL & OBJECTIVES STRATEGY IN ACTION PRODUCTS & SERVICES BUSINESS PERFORMANCE GROUP BUSINESS PERFORMANCE REGIONS BUSINESS
More informationLetter to Shareholders SEMI-ANNUAL REPORT 2008
Letter to Shareholders SEMI-ANNUAL REPORT 2008 Dear Shareholder You have in your hand the first shareholder letter issued by Nobel Biocare. Thanks to the conversion of Nobel Biocare s bearer shares into
More informationo Dental Implants Market By Material, Type, Structure Global Forecast To 2022 Report ID: MRDH Publishing Date: July, 2017
o Dental Implants Market By Material, Type, Structure Global Forecast To 2022 Report ID: MRDH-10401 Publishing Date: July, 2017 Sr. No. License Type Price 1 Single User License $4,175.00 2 Multiple User
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationGlobal Cosmetic Dentistry Market Research Report 2018
Report Information More information from: https://www.wiseguyreports.com/reports/3029111-global-cosmetic-dentistry-market-research-report- 2018 Global Cosmetic Dentistry Market Research Report 2018 Report
More informationInterim Report 1, The world leader in innovative evidence-based esthetic dental solutions
Interim Report 1, 2007 The world leader in innovative evidence-based esthetic dental solutions Disclaimer: This presentation contains forward-looking statements that are subject to various risk and uncertainties.
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationColoplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
More informationFor personal use only
Sirtex Medical Limited (ASX:SRX) Macquarie Inaugural Annual Emerging Healthcare Conference Mr Gilman Wong, CEO Mr Darren Smith, CFO Dr David Cade, CMO Wednesday, 10 October 2012 Macquarie Securities Group
More informationGlobal Invisible Braces Market: Trends, Opportunities and Forecasts ( )
Global Invisible Braces Market: Trends, Opportunities and Forecasts (2016-2021) By Types Clear Aligners, Ceramic, Lingual By Region Americas, Europe, Middle East, Africa, Asia-Pacific By Country- USA,
More informationNestlé Investor Seminar 2008
Nestlé Investor Seminar 2008 Nestlé Nutrition update on Acquisitions Richard Laube CEO Nestlé Nutrition 1 Disclaimer This presentation contains forward looking statements which reflect Management s current
More informationInternational Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1
Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia Slide 2 Forward-looking
More informationThe dental market. Facts, trends and dynamics.
14 Nobel Biocare Annual Report 2013 The dental market The dental market. Facts, trends and dynamics. Facts About 1.7 million licensed dentists worldwide, of which only just over 10% place implants About
More informationGlobal Dental Implant Market Research Report 2018
Report Information More information from: https://www.wiseguyreports.com/reports/3220035-global-dental-implant-market-research-report-2018 Global Dental Implant Market Research Report 2018 Report / Search
More informationGROWTH NOW! Franck Riboud
GROWTH NOW! Franck Riboud June 15 h, 2010 Disclaimer This document contains certain forward-looking statements concerning DANONE. Although DANONE believes its expectations are based on reasonable assumptions,
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationEnel Américas 1Q 2018 results
Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation
More informationGN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference. CEO GN ReSound, Mike van der Wallen September 3, 2008
GN Store Nord Goldman Sachs European Medtech and Healthcare Services Conference CEO GN ReSound, Mike van der Wallen September 3, 2008 GN Store Nord A/S GN GN Store Store Nord Nord Listed Listed company
More informationCPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018
CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm
More informationGoing Digital. Investora Gerhard Mahrle CFO COLTENE Holding AG. September 21, 2017
Investora 2017 Going Digital Gerhard Mahrle CFO COLTENE Holding AG September 21, 2017 COLTENE AN INTERNATIONALLY LEADING DEVELOPER, MANUFACTURER AND SELLER OF CONSUMABLES AND SMALL EQUIPMENT FOR DENTAL
More informationAn exciting combination in a high growth, high margin Nutrition category. Name of chairman
An exciting combination in a high growth, high margin Nutrition category 2 Vevey, December 14, 2006 Disclaimer This presentation contains forward looking statements which reflect Management s current views
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationBank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011
Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt Chairman of the Board of Management of Bayer HealthCare AG and Chairman of the Bayer HealthCare Executive Committee
More informationA GLOBAL LEADER IN PERSONALIZED NUTRITION
A GLOBAL LEADER IN PERSONALIZED NUTRITION Forward Looking Statements Management will make forward-looking statements during this presentation. Actual results could differ from those projected in such forward-looking
More informationThe New Danone : A unique food company. Autumn Conference 2008 CA Cheuvreux
The New Danone : A unique food company Autumn Conference 2008 CA Cheuvreux September 26th, 2008 Disclaimer This document contains certain forward-looking statements concerning Groupe DANONE. Although Groupe
More informationDelivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental
Delivering Results POSITIONED FOR GROWTH Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental PAUL GUGGENHEIM CEO, Patterson Dental Former owner and president, Guggenheim Brothers
More informationSCANNER & SERVICES OVERVIEW
SCANNER & SERVICES OVERVIEW Tim Mack VP BUSINESS DEVELOPMENT & GM ITERO 1 2014 Align Technology, Inc. 1 FORWARD LOOKING STATEMENT During this presentation and corresponding commentary we may make forwardlooking
More informationHyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
More informationColoplast A/S. Investor Presentation Investormøde 16. Januar 2006
Coloplast A/S Investor Presentation Investormøde 16. Januar 2006 2 Defining Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 5 areas: Ostomy
More informationGlobal Clear Aligner Market: Size, Trends & Forecasts ( ) August 2016
Global Clear Aligner Market: Size, Trends & Forecasts (2016-2020) August 2016 Global Clear Aligner Market Report Scope of the Report The report entitled Global Clear Aligner Market: Size, Trends & Forecasts
More informationTelekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationTECHNOLOGY & INNOVATION
TECHNOLOGY & INNOVATION Zelko Relic VP RESEARCH & DEVELOPMENT 1 2014 Align Technology, Inc. 1 FORWARD LOOKING STATEMENT During this presentation and corresponding commentary we may make forwardlooking
More informationMore information at
Report Information More information at https://www.htfmarketreport.com/reports/1288313 Global Homeopathic Products Market Professional Survey Report 2018 Report Code: HTF1288313 Pages: 111 Price: 1-User
More informationVITROLIFE AB (PUBL) Pareto Securities Health Care Conference
VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION
More informationProduct Information. Straumann CARES Scan & Shape Turning into digital solutions.
Product Information Turning into digital solutions. I have been using the Scan & Shape service since its introduction by Straumann. I have found it fast, reliable and cost-effective. The ability to preview
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More informationValue creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue
More informationGlobal Dental Market Report
Global Dental Market Report ----------------------------------------- Executive Summary The dental market comprises dental consumables and equipment. Dental consumables comprise all materials and consumables
More informationWorldwide Nanotechnology Dental Implants-- Markets Reach $8.1 By 2015
Worldwide Nanotechnology Dental Implants-- Markets Reach $8.1 By 2015 LEXINGTON, Massachusetts (March 14, 2009) WinterGreen Research announces that it has a new study on Worldwide nanotechnology dental
More informationConsolidated: Financial Summary
FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationMARCH 2014 RESULTS PRESENTATION Madrid, 2014
MARCH 2014 RESULTS PRESENTATION Madrid, 2014 Disclaimer In addition to figures prepared in accordance with IFRS, PRISA presents non-gaap financial performance measures, e.g., EBITDA, EBITDA margin, adjusted
More informationMarkets Leadership strengthened in a CHF 7 billion market
Management commentary Markets 49 Markets Leadership strengthened in a CHF 7 billion market THE CHF 24BN GLOBAL DENTAL MARKET BY CATEGORY AND IMPLANT SEGMENT SHARE Dental specialties (implants, endodontics,
More informationMerrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004
Merrill Lynch Pharmaceutical, Biotechnology & Medical Device Conference New York, February 4, 2004 Disclaimer 2 This presentation contains forward-looking statements, i.e., current estimates or expectations
More informationThird-quarter results 2013
Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationSTRAUMANN CARES DIGITAL SOLUTIONS. CARES Implant Prosthetics Ultimate restorative flexibility.
STRAUMANN CARES DIGITAL SOLUTIONS CARES Implant Prosthetics Ultimate restorative flexibility. Customized restorations of exceptional quality from one trusted partner. PERFORMANCE Reached through best-in-class
More informationWelcome to the Nine-Month Sales Conference
Welcome to the Nine-Month Sales Conference Nine-Month Sales Conference Paul Bulcke Nestlé CEO Nine-Month Sales Conference Wan Ling Martello Chief Financial Officer Disclaimer This presentation contains
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationGlobal Hearing Aid Battery Market: Analysis By Battery Type, By Region, By Country: Trends, Opportunities, Restraints (2018 Edition) Forecast to 2022
Global Hearing Aid Battery Market: Analysis By Battery Type, By Region, By Country: Trends, Opportunities, Restraints (2018 Edition) Forecast to 2022 By Value (In Million USD) By Volume (In Million Units)
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationNobelProcera Implant Bar Overdenture complete range of fixed and removable solutions.
NobelProcera Implant Bar Overdenture EXPERIENCE THE NEW WORLD OF CAD/CAM DENTISTRY 2 NobelProcera Implant Bar Overdenture NobelProcera Implant Bar Overdenture complete range of fixed and removable solutions.
More informationGlobal HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( )
Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) By Region- North America, Europe, APAC and RoW By Country - United
More informationFY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)
More informationProduct Information. Straumann CARES Scan & Shape Turn into digital.
Product Information Turn into digital. I have been using the Scan & Shape service since its introduction by Straumann. I have found it fast, reliable and cost-effective. The ability to preview the case
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationNutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS
Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor statement This presentation may contain forward-looking statements with respect to
More informationDesigning a Smoke-Free Future
Designing a Smoke-Free Future Morgan Stanley Global Consumer & Retail Conference New York, November 14, 2017 Jacek Olczak Chief Financial Officer Martin King President, Asia Region Forward-Looking and
More informationbiomérieux - First-Half 2009 Business Review
PRESS RELEASE biomérieux - First-Half 2009 Business Review First-Half 2009 Sales Up 6% at constant exchange rates and scope of consolidation Up 10.3% at constant exchange rates, including business development
More informationVITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar
VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar 2018-08-16 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION A Swedish
More informationLeading Intimate Healthcare. Investor presentation Q1 2007/08
Leading Intimate Healthcare Investor presentation Q1 2007/08 1 2 Agenda Introduction to Coloplast Q1 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate healthcare Appendices Q1
More informationGoing Digital. Swiss Equities Conference Bad Ragaz. Martin Schaufelberger CEO COLTENE Holding AG Gerhard Mahrle CFO COLTENE Holding AG
Swiss Equities Conference Bad Ragaz Going Digital Martin Schaufelberger CEO COLTENE Holding AG Gerhard Mahrle CFO COLTENE Holding AG January 11, 2018 COLTENE AN INTERNATIONALLY LEADING DEVELOPER, MANUFACTURER
More informationCorporate Presentation October New growth cycle and value innovation
Corporate Presentation October 2017 New growth cycle and value innovation Index 1 Dental benefits: an incipient sector in Brazil 2 Inside OdontoPrev 3 Strategic competitive advantages 4 Financial and Operational
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationDynamic Growth. Investora Gerhard Mahrle CFO COLTENE Holding AG. September 2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN. Investora 2018 Dynamic Growth Gerhard Mahrle CFO COLTENE Holding AG September 2018 COLTENE AN INTERNATIONALLY
More informationHuman Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS
Human Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS Safe harbor statement This presentation may contain forward-looking statements with respect to DSM s
More informationThe acquisition of Fortitech
The acquisition of Fortitech Accelerating DSM s strategy to become a full solutions provider in food ingredient blends Investor Relations 8 November 2012 Overview Fortitech at a glance Acquisition rationale
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More informationEfforts start to pay off in the fourth quarter
2014 annual sales (1 st January to 31 December 2014) Efforts start to pay off in the fourth quarter Double-digit growth for Food & Beverage in the US (excluding scope effect) Double-digit growth in emerging
More informationNobelProcera Implant Bar Overdenture EXPERIENCE THE NEW WORLD OF CAD/CAM DENTISTRY
NobelProcera Implant Bar Overdenture EXPERIENCE THE NEW WORLD OF CAD/CAM DENTISTRY 2 NobelProcera Implant Bar Overdenture NobelProcera Implant Bar Overdenture complete range of fixed and removable solutions.
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationWhole Grain and High Fiber - Global Market Outlook ( )
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Whole Grain and High Fiber - Global Market Outlook (2015-2022) Whole Grain and High Fiber - Global Market Outlook
More informationTABLE 4 U.S. TEETH CLEANING VISITS BY SELECTED CHARACTERISTICS (%) TABLE 4 (CONTINUED) FIGURE 2 U.S. POPULATION WITH TEETH CLEANING
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 METHODOLOGY... 2 ANALYST... 3 RELATED BCC STUDIES... 3 BCC ONLINE SERVICES... 3 DISCLAIMER...
More informationKAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO
KAPITALMARKNADSDAG 20 SEPTEMBER 2016 Thomas Axelsson, CEO 1 AGENDA 16.10-16.30 VD har ordet Thomas Axelsson, CEO 16.30-16.50 Clinical relevance of time-lapse Dr. Niels B. Ramsing, Business Unit Time-lapse,
More informationWilliam Demant. Jefferies Healthcare Conf. Nov Søren B. Andersson, VP Investor Relations
William Demant Jefferies Healthcare Conf. Nov. 2017 Søren B. Andersson, VP Investor Relations Agenda General update Key take-aways from November Interim Statement Hearing Devices Outlook 2017 Q&A 2 General
More informationALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT
ALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT ALLERGAN CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements contained in this presentation
More information